THE GENETIC TOXICOLOGY OF ACRIDINES

被引:129
作者
FERGUSON, LR
DENNY, WA
机构
[1] Cancer Research Laboratory, University of Auckland Medical School, Private Bag
来源
MUTATION RESEARCH | 1991年 / 258卷 / 02期
基金
英国医学研究理事会;
关键词
ACRIDINE AND DERIVATIVES; INTERCALATION BINDING TO DNA; DNA; BINDING OF ACRIDINE TO;
D O I
10.1016/0165-1110(91)90006-H
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Acridine and its derivatives are planar polycyclic aromatic molecules which bind tightly but reversibly to DNA by intercalation, but do not usually covalently interact with it. Acridines have a broad spectrum of biological activities, and a number of derivatives are widely used as antibacterial, antiprotozoal and anticancer drugs. Simple acridines show activity as frameshift mutagens, especially in bacteriophage and bacterial assays, by virtue of their intercalative DNA-binding ability. Acridines bearing additional fused aromatic rings (benzacridines) show little activity as frameshift mutagens, but interact covalently with DNA following metabolic activation (forming predominantly base-pair substitution mutations). Compounds where the acridine acts as a carrier to target alkylating agents to DNA (e.g. the ICR compounds) cause predominantly frameshift as well as base-pair substitution mutations in both bacterial and mammalian cells. Nitroacridines may act as simple acridines or (following nitro group reduction) as alkylating agents, depending upon the position of the nitro group. Acridine-based topoisomerase II inhibitors, although frameshift mutagens in bacteria and bacteriophage systems, are primarily chromosomal mutagens in mammalian cells. These mutagenic activities are important, since the compounds have considerable potential as clinical antitumour drugs. Although evidence suggests that simple acridines are not animal or human carcinogens, a number of the derived compounds are highly active in this capacity.
引用
收藏
页码:123 / 160
页数:38
相关论文
共 179 条
  • [1] NUCLEIC-ACID BINDING-DRUGS .12. X-RAY CRYSTALLOGRAPHIC AND CONFORMATIONAL STUDIES ON THE ANTI-CANCER DRUG META-AMSA AND ITS MESYL DERIVATIVE
    ABRAHAM, ZHL
    CUTBUSH, SD
    KURODA, R
    NEIDLE, S
    ACHESON, RM
    TAYLOR, GN
    [J]. JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 2, 1985, (03): : 461 - 465
  • [2] ALBERT A, 1962, ACRIDINES PREPARATIO
  • [3] A RAPID TECHNIQUE FOR THE QUANTITATION OF DNA-REPAIR SYNTHESIS IN THE HEPATOCYTE DNA-REPAIR TEST FOR CHEMICAL CARCINOGENS
    ALTHAUS, FR
    PITOT, HC
    [J]. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1983, 407 (JUN) : 463 - 466
  • [4] POINT MUTATIONS AT THE THYMIDINE KINASE LOCUS IN L5178Y MOUSE LYMPHOMA-CELLS .2. TEST VALIDATION AND INTERPRETATION
    AMACHER, DE
    PAILLET, SC
    TURNER, GN
    RAY, VA
    SALSBURG, DS
    [J]. MUTATION RESEARCH, 1980, 72 (03): : 447 - 474
  • [5] AMACHER DE, 1980, ANN NY ACAD SCI, V407, P239
  • [6] AMES BN, 1966, SPR COLD HARB S Q BI, V31, P211
  • [7] AMES BN, 1974, 11 P INT CANC C FLOR
  • [8] ARLIN Z, 1983, CANCER TREATMENT REP, V67, P96
  • [9] DNA-BINDING AND GROWTH INHIBITORY PROPERTIES OF A SERIES OF 2,7-DI-ALKYL-SUBSTITUTED DERIVATIVES OF PROFLAVINE
    BAGULEY, BC
    FERGUSON, LR
    DENNY, WA
    [J]. CHEMICO-BIOLOGICAL INTERACTIONS, 1982, 42 (01) : 97 - 105
  • [10] THE MUTAGENICITY OF DIBENZ[A,J]ACRIDINE, SOME METABOLITES AND OTHER DERIVATIVES IN BACTERIA AND MAMMALIAN-CELLS
    BONIN, AM
    ROSARIO, CA
    DUKE, CC
    BAKER, RSU
    RYAN, AJ
    HOLDER, GM
    [J]. CARCINOGENESIS, 1989, 10 (06) : 1079 - 1084